Infinium Pharmachem Limited (NSE:INFINIUM)
India · Delayed Price · Currency is INR 209.50
+4.45 (2.17%)
Jul 13, 2026, 3:28 PM IST
Infinium Pharmachem Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,896 | 1,557 | 1,357 | 1,142 | 991.19 |
| 1,896 | 1,557 | 1,357 | 1,142 | 991.19 | |
Revenue Growth (YoY) | 21.79% | 14.78% | 18.77% | 15.24% | 81.01% |
Cost of Revenue | 1,485 | 1,178 | 1,040 | 810.2 | 769.18 |
Gross Profit | 410.85 | 378.89 | 316.45 | 332.05 | 222.01 |
Selling, General & Admin | 86.73 | 87.88 | 65.86 | 57.95 | 38.23 |
Other Operating Expenses | 108.47 | 125.37 | 65.02 | 113.54 | 82.27 |
Operating Expenses | 225.81 | 246.19 | 157.56 | 184.88 | 127.88 |
Operating Income | 185.05 | 132.7 | 158.89 | 147.16 | 94.13 |
Interest Expense | -28.02 | -24.93 | -18.53 | -27.94 | -14.4 |
Interest & Investment Income | - | 0.89 | 1.82 | 0.2 | 0.3 |
Currency Exchange Gain (Loss) | - | 9.7 | 6.87 | 9.97 | 2.08 |
Other Non Operating Income (Expenses) | 21.38 | -2.65 | 3.06 | 0.15 | 4.21 |
EBT Excluding Unusual Items | 178.4 | 115.7 | 152.1 | 129.53 | 86.32 |
Pretax Income | 178.4 | 115.7 | 152.1 | 129.53 | 86.32 |
Income Tax Expense | 36.41 | 37.27 | 37.07 | 31.36 | 19.47 |
Earnings From Continuing Operations | 141.99 | 78.43 | 115.03 | 98.17 | 66.86 |
Minority Interest in Earnings | -20.49 | 3.02 | -2.01 | -3.27 | -5.79 |
Net Income | 121.5 | 81.45 | 113.02 | 94.9 | 61.06 |
Net Income to Common | 121.5 | 81.45 | 113.02 | 94.9 | 61.06 |
Net Income Growth | 49.17% | -27.93% | 19.10% | 55.41% | 124.55% |
Shares Outstanding (Basic) | 16 | 15 | 11 | 10 | 10 |
Shares Outstanding (Diluted) | 16 | 15 | 11 | 10 | 10 |
Shares Change (YoY) | 7.12% | 36.49% | 4.80% | - | - |
EPS (Basic) | 7.80 | 5.60 | 10.61 | 9.33 | 6.01 |
EPS (Diluted) | 7.80 | 5.60 | 10.61 | 9.33 | 6.01 |
EPS Growth | 39.29% | -47.21% | 13.64% | 55.41% | 124.55% |
Free Cash Flow | 240.49 | -343.76 | 14.06 | 11.23 | 70.69 |
Free Cash Flow Per Share | 15.44 | -23.64 | 1.32 | 1.10 | 6.95 |
Gross Margin | 21.67% | 24.33% | 23.33% | 29.07% | 22.40% |
Operating Margin | 9.76% | 8.52% | 11.71% | 12.88% | 9.50% |
Profit Margin | 6.41% | 5.23% | 8.33% | 8.31% | 6.16% |
Free Cash Flow Margin | 12.68% | -22.08% | 1.04% | 0.98% | 7.13% |
EBITDA | 215.65 | 165.64 | 185.57 | 160.55 | 100.44 |
EBITDA Margin | 11.37% | 10.64% | 13.68% | 14.06% | 10.13% |
D&A For EBITDA | 30.61 | 32.95 | 26.68 | 13.39 | 6.31 |
EBIT | 185.05 | 132.7 | 158.89 | 147.16 | 94.13 |
EBIT Margin | 9.76% | 8.52% | 11.71% | 12.88% | 9.50% |
Effective Tax Rate | 20.41% | 32.21% | 24.37% | 24.21% | 22.55% |
Revenue as Reported | 1,918 | 1,578 | 1,372 | 1,156 | 1,001 |
Advertising Expenses | - | 13.59 | 6.75 | 4.24 | 2.83 |